Centessa Pharmaceuticals Files Definitive Additional Materials

TL;DR

Centessa Pharma dropped more proxy docs, no fee needed.

AI Summary

Centessa Pharmaceuticals plc filed definitive additional materials on May 21, 2024, related to its proxy statement. The filing concerns the company's operations and shareholder matters, with no fee required for this submission.

Why It Matters

This filing provides updated information to shareholders regarding important company matters, ensuring they have the latest details before making decisions related to proxy voting.

Risk Assessment

Risk Level: low — This is a routine filing of additional proxy materials, not indicating any immediate financial or operational risks.

Key Players & Entities

• Centessa Pharmaceuticals plc (company) — Registrant
• 0001999371-24-006363 (filing_id) — Accession Number
• 20240521 (date) — Filing Date

FAQ

Key Financial Figures

• $256.6M — up’s total liquidity position was $256.6M (2022: $393.6M) and expects its existin
• $393.6M — l liquidity position was $256.6M (2022: $393.6M) and expects its existing cash and cash

Filing Documents

• centessa_defa14a.htm (DEFA14A) — 694KB
• centessadefa14a001.jpg (GRAPHIC) — 51KB
• centessadefa14a002.jpg (GRAPHIC) — 59KB
• centessadefa14a003.jpg (GRAPHIC) — 40KB
• cen_001.jpg (GRAPHIC) — 56KB
• cen_002.jpg (GRAPHIC) — 59KB
• cen_003.jpg (GRAPHIC) — 55KB
• 0001999371-24-006363.txt ( ) — 1133KB

FINANCIAL STATEMENTS FOR THE YEAR

FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023 ANNUAL REPORT AND FINANCIAL STATEMENTS INTRODUCTION AND CONTENTS Centessa Pharmaceuticals PLC (the “ Company ”, or the “ Parent Company ”) is a public limited company incorporated under the laws of England and Wales with American Depositary Shares (“ADS’s”) (representing its ordinary shares on a 1:1 basis) listed on the NASDAQ Global Select Market and traded under the symbol “CNTA”. To meet US securities law reporting requirements, the Company is required to file an annual report on Form 10-K with the United States Securities and Exchange Commission (the “ SEC ”), which includes the audited consolidated financial statements of the Company and its subsidiaries (the “Group”) prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). To meet UK statutory requirements for being a quoted company under the UK Companies Act 2006 (the “ Companies Act ”), the Company is required to file Consolidated financial statements. The contents of this Annual Report are as follows: Title Page(s) Company Information 2 A letter from our CEO 3 Strategic Report 5 Directors’ Report 11 Directors’ Remuneration Report 14 39 Independent Auditors’ Report 40 Company Balance Sheet 47 Company Statement of Changes in Equity 48 Notes to the Financial Statements 49 UK Statutory Disclosures Relevant to the Financial Statements 59 Annual Report on Form 10-K Appendix 1 This “ Annual Report ”, as mentioned throughout these UK financial documents, is comprised of the reports listed above and the Annual Report on Form 10-K (the “ Form 10-K ”) filed with the SEC on 19 March 2024. For

, Item 1: Business; Overview section of 10-K – p.5

Part I, Item 1: Business; Overview section of 10-K – p.5 the interest of the company’s employees Diversity and inclusion are important to the Group’s growth strategy and align with the Group’s values of integrity and equality. Appointments within the Group are made on merit according to a balance of skills and experience. Whilst acknowledging the benefits of diversity, individual appointments are made irrespective of personal characteristics such as race, disability, gender, sexual orientation, religion or age. A breakdown of employment statistics as of 31 December 2023 is as follows: Position Male Female Total Company Executive Director* 1 — 1 Executive Officers 4 2 6 All other Employees 35 30 65 Total Employees 40 32 72 Non-Executive Directors 5 2 7 Total Employees and Non-Executive Directors 45 34 79 ___________ * Chief Executive Office A breakdown of employment statistics as of 31 December 2022 is as follows: Position Male Female Total Company Executive Director* 1 — 1 Executive Officers 6 2 8 All other Employees 41 33 74 Total Employees 48 35 83 Non-Executive Directors 5 2 7 Total Employees and Non-Executive Directors 53 37 90 ___________ * Chief Executive Officer 8 The Board and Company management have a good relationship with the Group’s employees. The Board maintains constructive dialogue with employees through the Company’s Executive Leadership. Additionally, the Group conducts monthly town hall meetings for all of the Group’s employees to communicate important developments and provide a forum for exchange of questions & answers. The Group holds extended Leadership Team meetings to inform and collect feedback from senior managers from time to time. The Chief Executive Officer holds periodic ‘coffee chats’ which employees are encouraged to attend and which provide an informal, small group setting for empl

View Full Filing

View this DEFA14A filing on SEC EDGAR